Towa Pharmaceutical announced plans to begin exporting generic injectable drugs manufactured in Japan to the United States as early as 2028, according to CEO Yoshida [1]. The company aims to leverage its advanced quality control capabilities to establish a competitive position in the American pharmaceutical market [1]. Towa's expansion strategy includes a shift toward high-value-added injectable drugs [1]. The company's ability to pursue this US market entry was facilitated by its 2020 acquisition of a Spanish drugmaker, which provided Towa with an established U.S. sales network [1]. This move represents a significant internationalization effort for the Japanese pharmaceutical manufacturer, positioning it to compete in one of the world's largest pharmaceutical markets.
CONCLUSION
Towa Pharmaceutical's planned entry into the US generic injectables market by 2028 represents a strategic expansion leveraging its quality control expertise and existing US distribution infrastructure from its 2020 Spanish acquisition. This move signals the company's confidence in competing in the high-value injectable segment of the American pharmaceutical market.